Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SynAct Pharma AB ( (SE:SYNACT) ) has provided an update.
SynAct Pharma AB announced the execution of a second conversion of 1,000,000 warrants by Heights Capital Management, generating SEK 17.7 million. This financial boost strengthens SynAct’s financial position, extending its operational runway and enhancing its appeal to potential business and development partners.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm, focusing on resolving inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, helping patients achieve immune balance.
Average Trading Volume: 209,869
Technical Sentiment Signal: Hold
Current Market Cap: SEK947.2M
See more data about SYNACT stock on TipRanks’ Stock Analysis page.